tbuckley/cabot-search huggingface dataset:
Is there an indication for high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (PBSCT) in the treatment of patients with bone and soft-tissue sarcomas?
Authors: B. Kasper, T. Lehnert, L. Bernd, G. Egerer
Journal: Journal of Clinical Oncology (2005)

9079 Background: Whether HDCT with PBSCT improves the long-term outcome for patients with bone and soft-tissue sarcomas (STS) is debatable and controversial. Methods: From August 1998 to September 2004 30 patients (pts.) with bone and STS received HDCT and PBSCT (Ewing sarcoma family n = 9, osteosarcoma n = 6, chondrosarcoma n = 1, MPNST n = 4, synovial sarcoma n = 4, liposarcoma n = 2, leiomyosarcoma n = 2, rhabdomyosarcoma n = 1, meningosarcoma n = 1). Eighteen pts. were female, median age at TPL was 30.3 years [range: 13 - 59]. Following conventional chemotherapy with or without surgery CR (n = 10), PR (n = 11), SD (n = 3) and PD (n = 6) were reached prior PBSCT. Pts. received the ICE/PEI conditioning regimen containing of ifosfamide 2000 mg/m2/d 1–6, carboplatin 200 mg/m2/d 1–6 and etoposide 200 mg/m2/d 1–6 (n = 15) or equivalent. Results: One pt. died due to cardiac arrest after HDCT. Except hematologic complications, no WHO grade III-IV complications were observed. Five pts. died after PBSCT due to PD, in another nine pts. disease recurred and led to death, 15 pts. are alive with/without disease. For all pts., median progression-free survival (PFS) is 15.9 months [range: 0 - 90] and overall survival (OS) is 22.0 months [range: 0 - 90]. Interestingly, osteosarcomas, Ewing sarcoma family and chondrosarcoma (n = 16) demonstrate significant longer PFS and OS with 24.9 months [range: 0 - 90] and 29.6 months [range: 2 - 90] compared to STS (n = 14) with 5.6 months [0 - 18] and 13.3 months [range: 0 - 33], respectively. This survival advantage might be due to a significant longer follow-up in the bone sarcoma group with a median of 29.8 months [range: 2 - 90] compared to 13.3 months [range: 0 - 33] in the STS patients. Pts. in CR prior to HDCT (n = 10) showed a median PFS of 28.1 months [range: 3 - 67] and median OS of 34.4 months [range: 7 - 67]. Conclusions: Our data indicated that HDCT is an appropriate treatment strategy for pts. with bone and STS. Younger pts. with a good performance status in complete or partial remission prior to HDCT might derive benefit from HDCT within the context of an interdisciplinary treatment approach. No significant financial relationships to disclose.
Pitfalls in the Isolation of a Human Breast Carcinoma Virus in Tissue Culture&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Etienne Y. Lasfargues, William G. Coutinho, Dan H. Moore
Journal: JNCI Journal of the National Cancer Institute (1972)

Assuming that a human mammary tumor virus might be produced as in the mouse model, by the neoplastic epithelial cells, the finding of a virus particle budding from human breast tumor cells in culture would add strong support to the virus-inducing hypothesis. Monolayer cultures of human breast-tumor fragments, however, gave rise to an abundant fibroblastic outgrowth. Harvesting cells “spilling” out of tumor slices helped to select epithelial cell aggregates which grew relatively well in media supplemented with serum and amniotic fluid. When it was found that both serum and amniotic fluid contained virus-like particles, attempts were made to replace them by bactopeptones and lactalbumin hydrolysates which are autoclavable. Addition of Plasdone-C, an inert vinyl polymer, conferred to the solution the physical properties of serum. The serum-free media have supported the growth of human breast tumor epithelium for several months. Virus-like particles were found in these culture supernatants, but no virus particle budding from the cell membrane was observed.
Suicidal behavior among serious juvenile offenders
Authors: N E Alessi, M McManus, A Brickman, L Grapentine
Journal: American Journal of Psychiatry (1984)

Seventy-one incarcerated juvenile offenders were diagnosed according to DSM-III and assessed for suicidal behavior. Subjects diagnosed as having major affective disorders or borderline personality disorders showed the highest degree of suicidal tendency and had made the most serious attempts.
Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?
Authors: E van Nood, P Speelman, E  J Kuijper, J J Keller
Journal: Eurosurveillance (2009)

Patients with recurrent Clostridium difficile infections (CDI) in hospitals and the community constitute an increasing treatment problem. While most patients with a first infection respond to either metronidazole or oral vancomycin, therapy in recurrent C. difficile infections tends to fail repeatedly. Lack of alternative treatment options can be a tremendous burden, both to patients and their treating physicians. Most guidelines recommend prolonged oral vancomycin pulse and or tapering schedules, but evidence-based treatment strategies are lacking. The role of immunoglobulins, whey prepared from vaccinated cows, probiotics or other antibiotics is unclear. Since 1958 several case series and case reports describe a treatment strategy where faecal infusions are successfully given for the treatment of recurrent CDI. Restoring intestinal flora has been historically thought of as the mechanism responsible for cure in these patients. In the literature, more than 150 patients have received faeces from a healthy donor, either infused through an enema, or through a nasoduodenal or nasogastric tube. We summarise the literature regarding treatment with donor faeces for recurrent CDI, and introduce the FECAL trial, currently open for inclusion.
Clinical use of dronabinol.
Authors: T F Plasse
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.11.2079 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1658243 Clinical use of dronabinol. T F PlassexT F PlasseSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.11.2079 PDF "Clinical use of dronabinol.." Journal of Clinical Oncology, 9(11), pp. 2079–2080© 1991 by American Society of Clinical Oncology
Ongoing Prothrombotic State in Patients With Antiphospholipid Antibodies: A Role for Increased Lipid Peroxidation
Authors: Domenico Praticò, Domenico Ferro, Luigi Iuliano, Joshua Rokach, Fabrizio Conti, Guido Valesini, Garret A. FitzGerald, Francesco Violi
Journal: Blood (1999)
Phase I/II study of S-1 combined with triweekly irinotecan for advanced or recurrent colorectal cancer
Authors: Y. Kakeji, E. Oki, R. Yoshida, K. Ikeda, M. Ohta, T. Honboh, A. Egashira, N. Sadanaga, M. Morita, Y. Maehara
Journal: Journal of Clinical Oncology (2007)

14541 Background: A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced or recurrent colorectal cancer. Methods: The subjects were untreated patients with inoperable advanced or recurrent colorectal cancer aged 20–75 years. S-1 was administered orally at 80 mg m-2 day-1 from day 1 to 14 of a 21-day cycle and CPT-11 was given intravenously on day 1 at an initial dose of 80 mg m-2 day-1, stepping up to 150 mg m-2. The treatment was repeated every 3 weeks, unless disease progression was observed. Results: In the phase I portion, only one of six patients at level 1 (80 mg m-2 of CPT-11) developed DLT, grade 3 diarrhea. No other serious adverse reactions occurred (either hematological or non- hematological), and all patients at levels 2 (100 mg m-2) to 5 (150 mg m-2) could receive therapy safely on an outpatient basis. The final RD was determined to be 150 mg m-2. In the phase II portion, fourteen patients including three patients in the final RD phase I portion were evaluated. The median treatment course was six (range: 2–17). The incidences of severe (grade 3–4) haematological and nonhaematological toxicities were 41.7 and 8.3%, respectively, but all were manageable. The RR was 50% (7 of 14, 95%CI: 23.0–77.0%), and Disease Control Rate (PR + SD) was seen in 71.4%. MST is not reached. Conclusions: Our phase I/II trial showed that S-1 combined with CPT-11 achieved a high response rate and could be given safely on an outpatient basis. These findings suggest that the therapy has potential as first- line treatment for inoperable advanced recurrent colorectal cancer. The updated analysis will be presented at the meeting. No significant financial relationships to disclose.
Translational Childhood Cancer Genomics
Authors: Adam Shlien, David Malkin, Uri Tabori
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.
Authors: H. Choy, L. S. Schwartzberg, S. R. Dakhil, E. B. Garon, J. K. Choksi, R. Govindan, G. Peng, A. G. Koustenis, J. Treat, C. K. Obasaju
Journal: Journal of Clinical Oncology (2010)

7082 Background: There is no consensus chemotherapy regimen with concurrent radiation therapy (CRT) for inoperable stage IIIA/B non-small cell lung cancer (NSCLC). Pemetrexed (P) is synergistic with carboplatin (Cb) and cisplatin (C) in preclinical models. These doublets have shown efficacy and favorable toxicity profiles in metastatic disease in phase II/III trials. P, Cb, and C have activity as radiosensitizers. The objective of this study is to determine the toxicity, feasibility, response rates as well as of overall all survival (OS) of these doublets in stage III NSCLC. Methods: Pts with inoperable stage IIIA/B NSCLC were randomized to P 500 mg/m2 every 21 days combined with Cb AUC=5 (PCb) or C 75 mg/m2 (PC) IV every 21 days for 3 cycles. All pts received CRT 64–68 Gy (2 Gy/day, 5 days/week, Days 1–45). Consolidation P 500 mg/m2 IV every 21 days for 3 cycles began 3 wks after completion of chemoradiation. Primary endpoint of this ongoing trial is 2-year overall survival; secondary endpoints include toxicity, response rate, time to progression, and median survival. Results: Since June 2007, 71 pts have been evaluated, PCb: 34; PC: 38. Average dose compliance was PCb: 92.2% P, 90.2% Cb; PC: 90.4% P, 89.2% C. Average dose compliance for CRT was PCb: 91.2%, PC: 85.5%. Dose interruptions occurred with 23 pts. The PCb arm had 15 pts evaluable for response: CR, 1 (6.7%); PR, 6 (40.0%); SD, 7 (46.7%) and PD, 1 (6.7%). The PC arm had 20 evaluable pts: CR, 1 (5.0%); PR, 11 (55.0%), SD, 5 (25.0%) and PD, 3 (15.0%). Conclusions: Overall, P plus either Cb or C in combination with CRT appears well-tolerated in treatment of locally advanced NSCLC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly Lilly Lilly Lilly
A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC).
Authors: J. W. Leach, K. Swenson, E. Anderson, M. R. Menge, M. L. Tsai
Journal: Journal of Clinical Oncology (2010)

e18086 Background: S is an oral TKI which affects multiple pathways including VEGFR and PDGFR. Angiogenesis appears to play an important role in the biology of SCLC making it an attractive target for therapy. The only approved therapy for relapsed SCLC in the US is T which has no overlapping toxicities with S. Combining these strategies is a rational approach to treating SCLC although there is no reported data on the combination. Methods: We enrolled pts with relapsed or refractory SCLC previously treated with platinum containing chemotherapy. T was administered at 4 mg/m2 weekly × 3 every 28 days and S was administered in a 3+3 dose escalation design. The planned dose levels were 200 mg qd, 200 mg bid and 400 mg bid. Hematologic toxicity was not considered a S DLT and T dose modifications were planned to address this. Results: 16 pts were enrolled. 3 patients were treated in each of the first 2 dose levels with no DLT seen. 10 patients were treated at the 400 mg bid dose level. 3 DLTs were seen (1 grade 3 hand foot skin reaction, 1 grade 4 bowel perforation, 1 grade 3 anorexia). 1 of 6 patients in the first 2 cohorts developed grade 4 thrombocytopenia resulting in dose reduction of T. In the third cohort, 8 of 10 patients developed grade 3 thrombocytopenia causing dose reduction and delay. The study was terminated due to excessive thrombocytopenia. Conclusions: The combination of topotecan and sorafenib given on the schedule used in our trial was not tolerable due to excessive hematologic toxicity. Exploration of other schedules with this combination may be considered. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer
Real-time tracking mitochondrial dynamic remodeling with two-photon phosphorescent iridium (III) complexes
Authors: Huaiyi Huang, Liang Yang, Pingyu Zhang, Kangqiang Qiu, Juanjuan Huang, Yu Chen, JiaJie Diao, Jiankang Liu, Liangnian Ji, Jiangang Long, Hui Chao
Journal: Biomaterials (2016)
Transient Neurological Symptoms in Patients With Intracerebral Hemorrhage
Authors: Sandeep Kumar, Magdy Selim, Sarah Marchina, Louis R. Caplan
Journal: JAMA Neurology (2016)

Transient symptoms from an intracerebral hemorrhage (ICH) are not well recognized and have previously not been reported.To describe the clinical presentations and neuroimaging findings in a subset of patients with ICH presenting with transient neurological signs and symptoms.Clinical case series in which the hospital database of a large academic center in Boston, Massachusetts, was searched using International Classification of Diseases, Ninth Revision code 431 from June 1, 2000, to August 31, 2014, to identify patients with ICH who had transient deficits that resolved completely within 24 hours of symptom onset.Clinical presentation, neuroimaging findings, and prognosis.Among 3207 consecutive patients with ICH initially screened, 17 fulfilled study criteria (median age, 65 years [interquartile range, 56-73 years]; 11 male). In most patients, recovery from neurological symptoms started within a few hours after onset. Most hemorrhages in this cohort were small, with a mean (SD) hematoma volume of 17 (9.9) mL, and were subcortical in location. One patient died of hemorrhage recurrence.Patients with ICH can present with rapidly resolving deficits resembling transient ischemic attacks. Recognition of these instances is important to avoid delays in investigations and to manage these cases appropriately.
Bedside Ultrasonography for Diagnosis of Septic Shock
Authors: Robert C. Hyzy
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor size as a prognostic indicator in colon cancer (CCa) patients undergoing sentinel lymph node mapping (SLNM) versus conventional surgery (CS) in National Cancer Data Base (NCDB).
Authors: Mohammed Shaik, Sukamal Saha, Supriya Kumar Saha, Gregory Johnston, Alpesh K. Korant, David Wiese, Vikrom K. Dhar, David Eilander, Madan L. Arora, Trivor Singh
Journal: Journal of Clinical Oncology (2014)

411 Background: Unlike other solid tumors, tumor size (TS) is not included in TNM staging for CCa. We correlated TS with TNM staging and 5-year overall survival (5yrOS) for patients (pts) who underwent SLNM vs CS in NCDB. Methods: A retrospectively review of 312 CCa pts undergoing SLNM compared to 298,021 CCa pts from NCDB undergoing CS between 1996 and 2010 was done. The maximum diameter of the primary tumor as TS, T and Nodal status were reviewed. Pts in each group was subdivided into 4 groups: (&lt;2cm; 2-4cm; 4-6cm; &gt;6cm). Data were analyzed using Spearman’s rho correlation and Kaplan-Meier for 5yrOS. Hazard ratios (HR) were calculated using a Cox model adjusting for age, sex, grade, T, N-status, and TNM stage. Results: Pts with TS &lt;2 cm were mainly T1&amp;T2 (80.7%, 74.8%), whereas for tumors &gt;6cm, majority of pts were T3&amp;T4 (93.2%, 88.8%). T1&amp;T2 percentage consistently decreased as TS increased and T3&amp;T4 percentage consistently increased with TS (Table). Nodal positivity according to tumor size for SLNM were 17%, 49%, 56%, 46% and for CS were 18%, 38%, 48%, 51%, respectively. In both groups, nodal positivity increased as TS increased. The overall nodal positivity in both groups was 46% and 42%. For SLNM and CS, overall survival decreased as TS increased. Overall SLNM pts had better OS when compared to CS pts (65%, 54%). Conclusions: Nodal +vity and overall survival where slightly better in SLMN pts. Vs CS pts. TS had +ve correlation with T staging and N status in 5 yr OS. Hence, TS may be considered a prognostic factor in CCa pts. [Table: see text]
Targeting cyclin D1 for mantle cell lymphoma
Authors: Jingtao Chen
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Cyclin D1, an important component of cell cycle and a protein with known oncogenic potential, is over expressed in mantle cell lymphoma (MCL). MCL is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic
Hyperfractionated radiotherapy and concurrent low-dose daily carboplatin/paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study
Authors: B. Jeremic, B. Milicic, L. Acimovic, S. Milisavljevic
Journal: Journal of Clinical Oncology (2004)

7164 Background: Combined radiochemotherapy is considered the standard treatment for stage III nonsmall-cell lung cancer (NSCLC). We investigated the feasibility and activity of hyperfractionated radiation therapy (Hfx RT) and concurrent low-dose, daily carboplatin (C) and paclitaxel (P) in patients with Stage III NSCLC in a phase II trial. Methods: Sixty-four eligible patients started their treatment on day 1 with 30 mg/sqm of P during a 1-hr infusion. From the day 2 started Hfx RT using 1.3 Gy twice-daily (b.i.d.) to a total of 67.6 Gy and concurrent low-dose daily C, 25 mg/sqm and P, 10 mg/sqm, both given Mondays to Fridays during RT course. Daily P dose was administered using a 1-hr infusion scheduled to start at least 2 hours before the first daily fraction. Daily C was administered as short infusion administered 3–4 hr after the first daily RT fraction (i.e. 1.5–2 hr before the second one). Results: Objective response rate was 83% and included CR in 27 (42%) patients and PR in 26 (41%). Ten (16%) patients had a stable disease, while only one (2%) patient had progressive disease. The median survival time was 28 months, and 3- and 5-year survival rates were 37%, and 26%, respectively. The median time to local progression was 26 months and 3- and 5-year local progression-free survival rates were 37%, and 33%, respectively, while the median time to distant metastasis was 25 months, and 3- and 5- year distant metastasis-free survival rates were 37%, and 31%, respectively. No treatment-related deaths were observed during this study. Acute high-grade (≥ 3) toxicity was hematological (25%), esophageal (17%), bronchopulmonary (13%), and skin (9%) respectively. Late high-grade toxicity was infrequent. Conclusion: This combined Hfx RT/CP regimen produced excellent results which warrants its verification in a prospective randomized fashion. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb
Abstract 9350: Cerebral Perfusion and Cognitive Function in Post-Stroke Patients with Hypertension
Authors: Shuji Matsumoto, Megumi Shimodozono,, Tomokazu Noma,, Kazumi Kawahira
Journal: Circulation (2011)

Objective: To estimate cerebral perfusion and cognitive function in post-stroke patients with hypertension before and after hypotensive therapy. Research design and methods: The treatment group comprised 28 post-stroke patients (mean age ± standard deviation [SD], 57.8 ± 8.3 years) with previously untreated or ineffectively treated essential hypertension. All patients underwent brain xenon-enhanced computed tomography (Xe-CT) scanning and comprehensive neuropsychological testing, both before and after 24 weeks of hypotensive therapy using the angiotensin II receptor blocker (ARB) olmesartan medoxomil. The control group comprised 20 age-matched post-stroke patients (mean age ± SD, 56.6 ± 8.5 years) without hypertension, carotid atherosclerosis, coronary artery disease, or psychiatric disorders. Results: The hypertensive patients had significantly lower levels of cerebral perfusion (4-8%) in all brain regions, a 25% decrease in attention and psychomotor speed, and an 18% decrease in mentation compared with the control subjects. Following 6 months of hypotensive therapy, the hypertensive patients experienced an increase in cerebral perfusion by 8-15% in all brain regions, an 18-36% improvement in attention and psychomotor speed, and an average 19% improvement in abstract mentation. Conclusions: Hypertensive patients showed marked signs of cerebral hypoperfusion and impaired cognitive function, as indicated by decreased attention, reduced psychomotor speed, and slow mentation; however, these symptoms were improved by 24 weeks of hypotensive treatment with an ARB.